Jemima Kuehn1, Zareen Ismael2, Paul F Long2, Charlotte I S Barker3, Mike Sharland4. 1. Paediatric Infectious Diseases Unit, St George's Hospital, London, United Kingdom ; Cook County-Loyola-Provident Family Medicine Residency Program, Chicago, Illinois. 2. Institute of Pharmaceutical Science & Department of Chemistry, King's College, University of London, London, United Kingdom. 3. Paediatric Infectious Diseases Research Group, St George's University of London, London, United Kingdom. 4. Paediatric Infectious Diseases Unit, St George's Hospital, London, United Kingdom ; Paediatric Infectious Diseases Research Group, St George's University of London, London, United Kingdom.
Abstract
OBJECTIVES: Antibiotic-associated diarrhea (AAD) is a well-recognized adverse reaction to oral penicillins. This review analyzed the literature to determine the incidence of AAD following amoxicillin, amoxicillin/clavulanate, and penicillin V oral therapy in pediatric clinical trials. METHODS: An advanced search was conducted in MEDLINE and Embase databases for articles in any language reporting the incidence of AAD following oral penicillin therapy for any indicated infection in children (0-17 years). The search was limited to clinical trials. Articles were excluded if treatment was related to chronic conditions, involved concomitant antimicrobials, or if the dose or number of patients was not specified. RESULTS: Four hundred thirty-five articles relating to clinical trials were identified (307 from Embase; 128 from MEDLINE). Thirty-five articles reporting on 42 studies were included for analysis. The indications included acute otitis media, sinusitis, pharyngitis, and pneumonia. Thirty-three trials reported on amoxicillin/clavulanate, 6 on amoxicillin, and 3 on penicillin V. In total, the 42 trials included 7729 children who were treated with an oral penicillin. On average, 17.2% had AAD. Data were pooled for each penicillin. The AAD incidence was 19.8% for amoxicillin/clavulanate, 8.1% for amoxicillin, and 1.2% for penicillin V. The amoxicillin/clavulanate data were analyzed according to formulation: pooled-average. The incidence of ADD was 24.6% for the 4:1 formulation, 12.8% for the 7:1 formulation, 19.0% for the 8:1 formulation, and 20.2% for the 14:1 formulation. CONCLUSIONS: These results demonstrate substantially increased incidence of AAD following use of amoxicillin/clavulanate, compared to use of amoxicillin and penicillin V, as well as varying AAD rates with diffierent amoxicillin/clavulanate formulations. These findings warrant consideration when prescribing. The underlying mechanisms of AAD in children remain unclear.
OBJECTIVES: Antibiotic-associated diarrhea (AAD) is a well-recognized adverse reaction to oral penicillins. This review analyzed the literature to determine the incidence of AAD following amoxicillin, amoxicillin/clavulanate, and penicillin V oral therapy in pediatric clinical trials. METHODS: An advanced search was conducted in MEDLINE and Embase databases for articles in any language reporting the incidence of AAD following oral penicillin therapy for any indicated infection in children (0-17 years). The search was limited to clinical trials. Articles were excluded if treatment was related to chronic conditions, involved concomitant antimicrobials, or if the dose or number of patients was not specified. RESULTS: Four hundred thirty-five articles relating to clinical trials were identified (307 from Embase; 128 from MEDLINE). Thirty-five articles reporting on 42 studies were included for analysis. The indications included acute otitis media, sinusitis, pharyngitis, and pneumonia. Thirty-three trials reported on amoxicillin/clavulanate, 6 on amoxicillin, and 3 on penicillin V. In total, the 42 trials included 7729 children who were treated with an oral penicillin. On average, 17.2% had AAD. Data were pooled for each penicillin. The AAD incidence was 19.8% for amoxicillin/clavulanate, 8.1% for amoxicillin, and 1.2% for penicillin V. The amoxicillin/clavulanate data were analyzed according to formulation: pooled-average. The incidence of ADD was 24.6% for the 4:1 formulation, 12.8% for the 7:1 formulation, 19.0% for the 8:1 formulation, and 20.2% for the 14:1 formulation. CONCLUSIONS: These results demonstrate substantially increased incidence of AAD following use of amoxicillin/clavulanate, compared to use of amoxicillin and penicillin V, as well as varying AAD rates with diffierent amoxicillin/clavulanate formulations. These findings warrant consideration when prescribing. The underlying mechanisms of AAD in children remain unclear.
Entities:
Keywords:
amoxicillin; amoxicillin/clavulanate; antibiotic; antibiotic-associated diarrhea; oral penicillins; penicillin V
Authors: Marie-France de La Cochetière; Emmanuel Montassier; Jean-Benoit Hardouin; Thomas Carton; Françoise Le Vacon; Tony Durand; Valerie Lalande; Jean Claude Petit; Gilles Potel; Laurent Beaugerie Journal: Microb Ecol Date: 2010-02-26 Impact factor: 4.552
Authors: S E McLinn; M Moskal; J Goldfarb; F Bodor; G Aronovitz; R Schwartz; P Self; M J Ossi Journal: Antimicrob Agents Chemother Date: 1994-02 Impact factor: 5.191
Authors: Joshua Z Goldenberg; Stephanie S Y Ma; Jane D Saxton; Mark R Martzen; Per O Vandvik; Kristian Thorlund; Gordon H Guyatt; Bradley C Johnston Journal: Cochrane Database Syst Rev Date: 2013-05-31
Authors: M E Pichichero; S E Mclinn; W M Gooch; W Rodriguez; J Goldfarb; B E Reidenberg Journal: Pediatr Infect Dis J Date: 1995-07 Impact factor: 2.129
Authors: Nishchay Mehta; Anne Schilder; Ellen Fragaszy; Hannah E R Evans; Oliver Dukes; Logan Manikam; Paul Little; Sarah C Smith; Andrew Hayward Journal: J Antimicrob Chemother Date: 2017-03-01 Impact factor: 5.790
Authors: Aline Fuchs; Julia Bielicki; Shrey Mathur; Mike Sharland; Johannes N Van Den Anker Journal: Paediatr Int Child Health Date: 2018-11 Impact factor: 1.990
Authors: Shrey Mathur; Aline Fuchs; Julia Bielicki; Johannes Van Den Anker; Mike Sharland Journal: Paediatr Int Child Health Date: 2018-11 Impact factor: 1.990